|
Cefotaxime (INN) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, cefotaxime is a broad-spectrum antibiotic with activity against numerous Gram-positive and Gram-negative bacteria. Developed by Hoechst-Roussel Pharmaceuticals in the late 1980s, it was among the first third-generation ("extended spectrum") cephalosporins and the first of its class to become available in the United States. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. ==Medical uses== Given its broad spectrum of activity, cefotaxime is used for a variety of infections, including: * Lower respiratory tract infections - e.g. pneumonia (most commonly caused by ''S. pneumoniae'') * Genitourinary system infections - urinary tract infections (e.g. ''E. coli'', ''S. epidermidis'', ''P. mirabilis'') and cervical/urethral gonorrhea * Gynecologic infections - e.g. pelvic inflammatory disease, endometritis, and pelvic cellulitis * Bacteremia/septicemia - secondary to ''Streptococcus'' spp., ''S. aureus'', ''E. coli'', and ''Klebsiella'' spp. * Intra-abdominal infections - e.g. peritonitis * Bone and join infections - ''S. aureus'', ''Streptococcus'' spp. * CNS infections - e.g. meningitis/ventriculitis secondary to ''N. meningitidis'', ''H. influenzae'', ''S. pneumoniae''〔 Although cefotaxime has demonstrated efficacy in these infections, it is not necessarily considered to be the first-line agent. In meningitis, cefotaxime crosses the blood–brain barrier better than cefuroxime. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Cefotaxime」の詳細全文を読む スポンサード リンク
|